The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N06 | Psychoanaleptics | |
3 | N06D | Anti-dementia drugs | |
4 | N06DA | Anticholinesterases |
Code | Title | |
---|---|---|
N06DA01 | Tacrine | |
N06DA02 | Donepezil | |
N06DA03 | Rivastigmine | |
N06DA04 | Galantamine | |
N06DA05 | ||
N06DA52 | Donepezil and memantine | |
N06DA53 |
Active Ingredient | Description | |
---|---|---|
Donepezil |
Donepezil hydrochloride is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in the brain. Donepezil hydrochloride is in vitro over 1000 times more potent an inhibitor of this enzyme than of butyrylcholinesterase, an enzyme that is present mainly outside the central nervous system. |
|
Galantamine |
Galantamine, a tertiary alkaloid is a selective, competitive and reversible inhibitor of acetylcholinesterase. In addition, galantamine enhances the intrinsic action of acetylcholine on nicotinic receptors, probably through binding to an allosteric site of the receptor. As a consequence, an increased activity in the cholinergic system associated with improved cognitive function can be achieved in patients with dementia of the Alzheimer type. |
|
Ipidacrine |
|
|
Rivastigmine |
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer’s disease and Parkinson’s disease. |
Title | Information Source | Document Type | |
---|---|---|---|
ARICEPT Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
ARICEPT Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CONSION XL Prolonged-release capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DONECEPT Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
DOZEPT Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
EXELON Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
EXELON Transdermal patch | European Medicines Agency (EU) | MPI, EU: SmPC | |
GALSYA Prolonged-release capsule, hard | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
NIMVASTID Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |